These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 31230400)

  • 41. Early evolutionary divergence between papillary and anaplastic thyroid cancers.
    Capdevila J; Mayor R; Mancuso FM; Iglesias C; Caratù G; Matos I; Zafón C; Hernando J; Petit A; Nuciforo P; Cameselle-Teijeiro JM; Álvarez C; Recio JA; Tabernero J; Matias-Guiu X; Vivancos A; Seoane J
    Ann Oncol; 2018 Jun; 29(6):1454-1460. PubMed ID: 29648575
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma.
    Wang HM; Huang YW; Huang JS; Wang CH; Kok VC; Hung CM; Chen HM; Tzen CY
    Ann Surg Oncol; 2007 Oct; 14(10):3011-8. PubMed ID: 17638058
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
    Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
    Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
    Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
    Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary Squamous Cell Carcinoma of the Thyroid Has a Molecular Genetic Profile Distinct From That of Anaplastic Thyroid Carcinoma: A Whole Exome Sequencing and Gene Expression Profiling Study.
    Ye M; Guo Z; Xu J; Jin Y; He X; Ge M
    Am J Surg Pathol; 2024 Aug; 48(8):1024-1031. PubMed ID: 38775423
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation.
    Zhang K; Wang X; Wei T; Li Z; Zhu J; Chen YW
    Front Endocrinol (Lausanne); 2024; 15():1347362. PubMed ID: 38544687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
    Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
    Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 49. Predictive value of hematologic parameters and clinicopathological features of poorly differentiated thyroid carcinoma and anaplastic thyroid carcinoma.
    Huang D; Zhang J; Zheng X; Gao M
    Langenbecks Arch Surg; 2024 Aug; 409(1):241. PubMed ID: 39105980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
    Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
    Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary squamous cell carcinoma of thyroid with a novel BRAF mutation and High PDL-1 expression: A case report with treatment implications and review of literature.
    Torrez M; Braunberger RC; Yilmaz E; Agarwal S
    Pathol Res Pract; 2020 Oct; 216(10):153146. PubMed ID: 32853962
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
    Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
    Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
    Liu X; Bishop J; Shan Y; Pai S; Liu D; Murugan AK; Sun H; El-Naggar AK; Xing M
    Endocr Relat Cancer; 2013 Aug; 20(4):603-10. PubMed ID: 23766237
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
    Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
    J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutation profiles of follicular thyroid tumors by targeted sequencing.
    Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
    Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience.
    Romei C; Tacito A; Molinaro E; Piaggi P; Cappagli V; Pieruzzi L; Matrone A; Viola D; Agate L; Torregrossa L; Ugolini C; Basolo F; De Napoli L; Curcio M; Ciampi R; Materazzi G; Vitti P; Elisei R
    Oncol Lett; 2018 Jun; 15(6):9174-9182. PubMed ID: 29805648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
    Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparing outcomes in poorly-differentiated versus anaplastic thyroid cancers treated with radiation: a surveillance, epidemiology, and end results analysis.
    Arora S; Christos P; Pham A; Desai P; Wernicke AG; Nori D; Chao KS; Parashar B
    J Cancer Res Ther; 2014; 10(3):526-30. PubMed ID: 25313732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.